🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📢Today, we share the #Review "#Photodynamic Therapy for #Glioblastoma: Illuminating the Path toward Clinical Applicability" 👨‍🔬by Debarati Bhanja, et al. Penn State Health 📌Access the full paper here: mdpi.com/2072-6694/15/1…

🧠 An article discussing the molecular interactions between metastases and immune cells within the leptomeninges is now available in @nature.com. 🔗 nature.com/articles/s4158… #EANOessentials #glioblastoma #NeuroOncology #leptomeningeal #metastases

Critical to always consider clinical trials, especially considering that most brain tumor operations are not emergencies and there is often some time to evaluate your options! American Brain Tumor Association National Brain Tumor Society Brain Tumor Network Glioblastoma Research Organization Glioblastoma Foundation CURE GLIOBLASTOMA

WeTrials – Thinking about Joining a Clinical Trial? WeTrials oncodaily.com/blog/wetrials-… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #WeTrials

“It hits you like a ton of bricks…” Janet Fanaki shares what it’s like to hear the words “brain tumor” and how caregivers can find strength, answers, and support. 🎥 Caregiver Chronicles Ep. 2 is now live with WeTrials 📺 Watch full episode on Youtube:

Final Update CATNON ASCO 2025 · Median F/U 11 yrs · NO sig benefit concurrent TMZ · Sig benefit (HR 0.54) Adjuvant TMZ in IDHm (median OS 12.5 years) · NO benefit w/TMZ for IDHwt

Honored to be recognized as the Pennsylvania Medical Society Top 40 under 40. Grateful for my patients, colleagues and mentors who inspire me daily to keep pushing for better answers. Sean S. Mahase, MD Penn State Neurosurgery PennStateGME #Cancer bit.ly/43tLTZw

More evidence that ADCs are active in the CNS. This should be the end of automatic exclusions of patients with active brain mets from ADC trials.

Check out our first ever #SNO fireside chat with our inaugural guest Dr. Susan Chang UC San Francisco. Part of the SNO Young Investigator Committee initiative. Jake Young, MD Jasia Mahdi youtu.be/X2Tqc72myXE?si…

Congrats Stephen Bagley DrORourke and colleagues Penn Medicine - Abramson Cancer Center on their manuscript in Nature Medicine showing safety and early efficacy of bivalent CAR T cells in 18 patients with recurrent #glioblastoma! nature.com/articles/s4159…

🚨Update Randomized Trial: Significantly Better KPS & Cognitive Function with SRS compared to HA-WBRT for 5-20 brain mets 🚨🚨🚨

Neuro-onc study alert 🧠 Ashley Love Sumrall, MD, FACP, FASCO presents research that shows dordaviprone (ONC201) is effective and safe for treating recurrent H3 K27M-mutant diffuse midline glioma. With positive responses in both adults and kids, it offers hope. #ASCO25 Link: bit.ly/4kmIX8v

🧠 Early career in #neurooncology? Join Dr. Patrick Wen for SNO’s next Ask Me ‘Almost’ Anything (AMAA)! Patrick Y. Wen SNO Jasia Mahdi Jake Young, MD June 18 | 12–12:30pm ET Register & submit questions in the Early Career Community on SNO Central! snocentral.soc-neuro-onc.org

Brain Cancer Canada is More Than Just a Nonprofit. Together, we’re making every dollar count, because our loss has been profound and the need for change is urgent. NO WAGES OR SALARIES Brain Cancer Canada is a volunteer-led organization which ensures that more of your donations

Have questions about brain tumors, trials, or careers in neuro-oncology? Ask Dr. Patrick Wen during SNO’s AMAA session! 🗓️ June 18 | 12pm ET 💬 Post questions 24 hours ahead in SNO Central 🔗 Join: snocentral.soc-neuro-onc.org #SNOAMAA #medicalstudents #btsm #careersinneurooncology

We had anecdotally noticed a drop in rate of melanoma brain metastases over the years, since the implementation of immunotherapy. This investigation suggests potential prophylactic role of dual agent IT, particularly driven by PD1 blockers. Debarati Bhanja Manmeet Ahluwalia, MD, MBA, FASCO

Congratulations to UCSF School of Medicine Mulki Mehari for publishing science.org/doi/epdf/10.11…. Despite the goal of maximizing enrollment of brain cancer patients in clinical trials, many studies fail to meet recruitment targets.

Too many seniors with cancer face delays accessing FDA-approved therapies due to Medicare policies. In her op-ed for The Hill, ABTA CEO Kelly Sitkin calls on Congress to pass the Ensuring Patient Access to Critical Breakthrough Products Act of 2025. ow.ly/UVkj50W6mko

Make sure to sign up and leave your questions on SNO Central! Jake Young, MD Jasia Mahdi